ClinicalTrials.gg
CompletedNCT05459688Updated Dec 16, 2024Results posted

Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124

A Phase 2 interventional study of CIN-107 in Hypertension, sponsored by AstraZeneca. Completed at 36 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
175
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing baxdrostat in Hypertension — 2 open to participants now, 4 under way, 3 of them phase 3. baxdrostat · Hypertension.

Enrollment
10th of 18
175 · median 197
Started
2022
with 1 other
Phase 2
5 of 18
none open now
Registered
3rd of 18
by date
Lead sponsor
16 of 18
AstraZeneca

Among the 18 studies testing baxdrostat in Hypertension, this one is the 10th largest by enrollment, is one of 2 that started in 2022, is one of 5 in phase 2, and was the 3rd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 18 studies testing baxdrostat in Hypertension are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About baxdrostat

baxdrostat: first FDA approval 2026 (BAXFENDY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baxdrostat in Hypertension, or all of them as a file.
02

Study summary

This is a Phase 2, multicenter, open-label extension (OLE) study to evaluate the long-term safety, tolerability, and effectiveness of CIN-107 for up to 52 weeks in patients with HTN who have completed Part 1 or Part 2 of Study CIN-107-124. The study will be conducted at clinical sites that have participated in the double-blind, Phase 2 Study CIN-107-124.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have completed Part 1 or Part 2 of Study CIN-107-124;
  2. Have had acceptable safety and tolerability during Study CIN-107-124 as determined by the Investigator or Medical Monitor;
  3. Have demonstrated ≥70% and ≤120% adherence to their single background antihypertensive agent and the CIN-107 placebo during Study CIN-107-124;
  4. Agree to comply with the and reproduction restrictions of the study as follows:

    • Male patients must agree to abstain from sperm donation from Day 1 through 90 days after the final dose of study drug;
    • Female patients of (ie, ovulating, pre-menopausal, and not surgically sterile) must have a documented negative serum pregnancy test at enrollment (Visit 1); and
    • Female patients of childbearing potential must use a highly effective method of contraception (ie, \<1% failure rate) from Day 1 through 30 days after the last administration of study drug.
  5. Are able and willing to give for participation in the clinical study.

Exclusion criteria

Exclusion Criteria:

  1. Have met Protocol-defined stopping criteria, were withdrawn from the study, discontinued CIN-107 at the time of Visits 6 or 9, or were not compliant with the Protocol during Study CIN-107-124;
  2. Have received treatment with any agent for disease intervention (ie, other than study drug) during Study CIN-107-124, or since the last administration of study drug in Study CIN-107-124, or plans to participate in another clinical study within 30 days of discontinuation of study drug;
  3. Have had any new, significant, or uncontrolled comorbidity since initially enrolling in Study CIN-107-124 that would increase the risk of the patient in Study CIN-107-130, as determined by the Investigator;
  4. Have had a mean seated SBP ≥170 mmHg or DBP ≥105 mmHg at the end of Part 1 or Part 2 of Study CIN-107-124;
  5. Have an upper arm circumference that does not meet the cuff measurement criteria for the selected BP machine at Visit 1 of Study CIN-107-130;
  6. Have any uncontrolled or laboratory abnormality that would affect safety, interpretation of study data, or the patient's participation in the study, as determined by the Investigator;
  7. Have experienced a de novo or reactivated serious viral infection such as , , or during Study CIN-107-124;
  8. Have had any major episode of infection requiring hospitalization or treatment with intravenous antibiotics during Study CIN-107-124;
  9. Have developed a (with the exception of non-serious local and resectable basal or squamous cell carcinoma of the skin) during Study CIN-107-124;
  10. Have anticipated initiation of erythropoietin-stimulating agents and/or planned transfusion within 2 months after enrollment (Visit 1);
  11. Are expected to receive or are receiving any of the exclusionary drugs (strong cytochrome P450 3A inducers);
  12. Have known secondary causes of HTN (eg, renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, hyperparathyroidism, pheochromocytoma, Cushing's syndrome, or aortic coarctation) except obstructive sleep apnea;
  13. Have been diagnosed with stage III or IV chronic heart failure during Study CIN-107-124;
  14. Have had a stroke, , hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure during Study CIN-107-124;
  15. Have a known current severe left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy and/or severe aortic valvular disease diagnosed from a prior echocardiogram;
  16. Have a planned coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG]) or any major surgical procedure;
  17. Have had a CABG or other major cardiac surgery (eg, valve replacement), peripheral arterial bypass surgery, or PCI during Study CIN-107-124;
  18. Have a planned dialysis or kidney transplant during the course of this study;
  19. Have a known to CIN-107 or drugs of the same class, or any of its ;
  20. Have any clinically relevant medical or surgical conditions (including unstable conditions and/or treatment with systemic including ) that, in the opinion of the Investigator, would put the patient at risk by participating in the study;
  21. Are pregnant, breastfeeding, or planning to become pregnant during the study; or
  22. Are considered to be unsuitable for any other reason that may either place the patient at increased risk during participation or interfere with the interpretation of the study outcomes by the Investigator, after reviewing medical and psychiatric history, physical examination, and laboratory evaluation.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Experimental 2 mg CIN-107 tablets QD

    Treatment with 2 mg CIN-107 tablets, by mouth, once per day. Starting at Visit 1 and concluding at EOT (Visit 7).

    Drug: CIN-107

Interventions

  • 2 mg of CIN-107, once a day for 52 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Treatment-emergent Adverse Events (TEAEs)

    An AE was defined as any untoward medical occurrence in a clinical investigation participants administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and/or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational medicinal product, whether or not related to the investigational medicinal product. Any medical condition already present at enrollment should be recorded as medical history and not be reported as an AE unless the medical condition or signs or symptoms present at baseline changes in severity, frequency, or seriousness at any time during the study. In this case, it was be reported as an AE.

    Time frame: 52 weeks

  2. Number of Participants With Any Treatment-emergent Adverse Events of Special Interest (AESIs)

    For this study, AESIs include the following: Events of hypotension that require clinical intervention; Abnormal potassium laboratory values that require clinical intervention; and Abnormal sodium laboratory values that require clinical intervention.

    Time frame: 52 weeks

  3. Number of Participants With Any Treatment-emergent Serious Adverse Events (TESAEs)

    An AE was or adverse reaction is considered serious if, in the view of either the Investigator or Sponsor, it results in any of the following outcomes: Death, a life-threatening AE, a persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly/birth defect, or an important medical event.

    Time frame: 52 weeks

  4. Change From Baseline in Serum Potassium

    Mean change from baseline at Week 52 in serum potassium (mmol/L).

    Time frame: 52 weeks

  5. Change From Baseline in Serum Sodium

    Mean change from baseline at Week 52 in serum sodium (mmol/L).

    Time frame: 52 weeks

  6. Change From Baseline in Body Weight

    Change from baseline at 52 weeks in body weight (kg)

    Time frame: 52 weeks

  7. Change From Baseline in Temperature

    Change from baseline at 52 weeks in temperature (C)

    Time frame: 52 weeks

  8. Change From Baseline in Seated Heart Rate

    Change from baseline at 52 weeks in seated heart rate (beats/min)

    Time frame: 52 weeks

Secondary outcomes

  1. Change From Baseline in Mean Seated Systolic Blood Pressure

    Mean change from baseline at Week 52 in seated systolic blood pressure (SBP)

    Time frame: 52 weeks

  2. Change From Baseline in Mean Seated Diastolic Blood Pressure

    Mean change from baseline at 52 weeks in mean seated diastolic blood pressure (DBP)

    Time frame: 52 weeks

  3. Achieving Mean Seated Systolic Blood Pressure <130 mmHg

    Number of participants achieved mean seated systolic blood pressure (SBP) \<130 mmHg at 52 week

    Time frame: 52 weeks

  4. Non-responders in Study CIN-107-124 Achieving a Seated SBP Response <130 mmHg

    Number of non-responders (participants with seated SBP \>=130 mmHg) in Study CIN-107-124 achieving a seated SBP response \<130 mmHg with CIN-107 with/without a single background antihypertensive agent and/or rescue medication and irrespective of Study CIN-107-124 dose strength.

    Time frame: 52 weeks

  5. Responders in Study CIN-107-124 Achieving a Seated SBP Response <130 mmHg

    Number of responders (participants with \<130 mmHg) in Study CIN-107-124 achieving a seated SBP response \<130 mmHg with CIN-107 with/without a single background antihypertensive agent and/or rescue medication and irrespective of Study CIN-107-124 dose strength.

    Time frame: 52 weeks

07

Results

Posted Dec 16, 2024

Participant flow

Participant flow — Overall Study
Milestone2mg CIN-107
Started175
Completed146
Not completed29
Withdrew: Lost to follow-up6
Withdrew: Physician decision1
Withdrew: Withdrawal by subject19
Withdrew: Noncompliance, subject unable to complete last visit.3

Outcome measures

PrimaryNumber of Participants With Any Treatment-emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in a clinical investigation participants administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and/or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational medicinal product, whether or not related to the investigational medicinal product. Any medical condition already present at enrollment should be recorded as medical history and not be reported as an AE unless the medical condition or signs or symptoms present at baseline changes in severity, frequency, or seriousness at any time during the study. In this case, it was be reported as an AE.

Time frame:
52 weeks
Reported as:
Number · Participants
Number of Participants With Any Treatment-emergent Adverse Events (TEAEs)
Participants2mg CIN-107
Number of Participants With Any Treatment-emergent Adverse Events (TEAEs)73
PrimaryNumber of Participants With Any Treatment-emergent Adverse Events of Special Interest (AESIs)

For this study, AESIs include the following: Events of hypotension that require clinical intervention; Abnormal potassium laboratory values that require clinical intervention; and Abnormal sodium laboratory values that require clinical intervention.

Time frame:
52 weeks
Reported as:
Number · Participants
Number of Participants With Any Treatment-emergent Adverse Events of Special Interest (AESIs)
Participants2mg CIN-107
Number of Participants With Any Treatment-emergent Adverse Events of Special Interest (AESIs)7
PrimaryNumber of Participants With Any Treatment-emergent Serious Adverse Events (TESAEs)

An AE was or adverse reaction is considered serious if, in the view of either the Investigator or Sponsor, it results in any of the following outcomes: Death, a life-threatening AE, a persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly/birth defect, or an important medical event.

Time frame:
52 weeks
Reported as:
Number · Participants
Number of Participants With Any Treatment-emergent Serious Adverse Events (TESAEs)
Participants2mg CIN-107
Number of Participants With Any Treatment-emergent Serious Adverse Events (TESAEs)8
PrimaryChange From Baseline in Serum Potassium

Mean change from baseline at Week 52 in serum potassium (mmol/L).

Time frame:
52 weeks
Reported as:
Mean · mmol/L
Change From Baseline in Serum Potassium
mmol/L2mg CIN-107
Change From Baseline in Serum Potassium0.08 ± 0.417
PrimaryChange From Baseline in Serum Sodium

Mean change from baseline at Week 52 in serum sodium (mmol/L).

Time frame:
52 weeks
Reported as:
Mean · mmol/L
Change From Baseline in Serum Sodium
mmol/L2mg CIN-107
Change From Baseline in Serum Sodium0.6 ± 3.02
SecondaryChange From Baseline in Mean Seated Systolic Blood Pressure

Mean change from baseline at Week 52 in seated systolic blood pressure (SBP)

Time frame:
52 weeks
Reported as:
Mean · mmHg
Change From Baseline in Mean Seated Systolic Blood Pressure
mmHg2mg CIN-107
Change From Baseline in Mean Seated Systolic Blood Pressure-5.1 ± 11.51
SecondaryChange From Baseline in Mean Seated Diastolic Blood Pressure

Mean change from baseline at 52 weeks in mean seated diastolic blood pressure (DBP)

Time frame:
52 weeks
Reported as:
Mean · mmHg
Change From Baseline in Mean Seated Diastolic Blood Pressure
mmHg2mg CIN-107
Change From Baseline in Mean Seated Diastolic Blood Pressure-3.6 ± 8.65
PrimaryChange From Baseline in Body Weight

Change from baseline at 52 weeks in body weight (kg)

Time frame:
52 weeks
Reported as:
Mean · kg
Change From Baseline in Body Weight
kg2mg CIN-107
Change From Baseline in Body Weight-0.30 ± 3.839
PrimaryChange From Baseline in Temperature

Change from baseline at 52 weeks in temperature (C)

Time frame:
52 weeks
Reported as:
Mean · Celsius
Change From Baseline in Temperature
Celsius2mg CIN-107
Change From Baseline in Temperature-0.03 ± 0.473
PrimaryChange From Baseline in Seated Heart Rate

Change from baseline at 52 weeks in seated heart rate (beats/min)

Time frame:
52 weeks
Reported as:
Mean · beats/min
Change From Baseline in Seated Heart Rate
beats/min2mg CIN-107
Change From Baseline in Seated Heart Rate0.9 ± 9.49
SecondaryAchieving Mean Seated Systolic Blood Pressure <130 mmHg

Number of participants achieved mean seated systolic blood pressure (SBP) \<130 mmHg at 52 week

Time frame:
52 weeks
Reported as:
Number · Participants
Achieving Mean Seated Systolic Blood Pressure <130 mmHg
Participants2mg CIN-107
Achieving Mean Seated Systolic Blood Pressure <130 mmHg102
SecondaryNon-responders in Study CIN-107-124 Achieving a Seated SBP Response <130 mmHg

Number of non-responders (participants with seated SBP \>=130 mmHg) in Study CIN-107-124 achieving a seated SBP response \<130 mmHg with CIN-107 with/without a single background antihypertensive agent and/or rescue medication and irrespective of Study CIN-107-124 dose strength.

Time frame:
52 weeks
Reported as:
Number · Participants
Non-responders in Study CIN-107-124 Achieving a Seated SBP Response <130 mmHg
Participants2mg CIN-107
Non-responders in Study CIN-107-124 Achieving a Seated SBP Response <130 mmHg20
SecondaryResponders in Study CIN-107-124 Achieving a Seated SBP Response <130 mmHg

Number of responders (participants with \<130 mmHg) in Study CIN-107-124 achieving a seated SBP response \<130 mmHg with CIN-107 with/without a single background antihypertensive agent and/or rescue medication and irrespective of Study CIN-107-124 dose strength.

Time frame:
52 weeks
Reported as:
Number · Participants
Responders in Study CIN-107-124 Achieving a Seated SBP Response <130 mmHg
Participants2mg CIN-107
Responders in Study CIN-107-124 Achieving a Seated SBP Response <130 mmHg82

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2mg CIN-1070/175 (0%)8/175 (4.6%)20/175 (11.4%)
Most frequent serious events
Most frequent serious events
Event2mg CIN-107
Lacunar strokeNervous system disorders1/175
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/175
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/175
Angina pectorisCardiac disorders1/175
BradycardiaCardiac disorders1/175
Myocardial infarctionCardiac disorders1/175
DiverticulitisInfections and infestations1/175
Femoral nerve injuryInjury, poisoning and procedural complications1/175
Joint dislocationInjury, poisoning and procedural complications1/175
HyperkalaemiaMetabolism and nutrition disorders1/175
Most frequent other events
Most frequent other events
Event2mg CIN-107
Urinary tract infectionInfections and infestations13/175
HyperkalaemiaMetabolism and nutrition disorders9/175

Baseline characteristics

Age, Continuous
Age, Continuous(Years)2mg CIN-107
Mean60.6 ± 10.4
Age, Customized
Age, Customized(Participants)2mg CIN-107
> 75 years11
<= 75 years164
Sex: Female, Male
Sex: Female, Male(Participants)2mg CIN-107
Female78
Male97
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)2mg CIN-107
Hispanic or Latino99
Not Hispanic or Latino76
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)2mg CIN-107
American Indian or Alaska Native0
Asian4
Black or African American42
Native Hawaiian or other Pacific Islander0
Other1
White128
08

Study locations

36 sites
  • Research Site
    Saraland, Alabama 36571, United States
  • Research Site
    Huntington Park, California 90255, United States
  • Research Site
    Lincoln, California 95648, United States
  • Research Site
    Los Angeles, California 90057, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    Oceanside, California 92056, United States
  • Research Site
    Panorama City, California 91402, United States
  • Research Site
    Van Nuys, California 91405, United States
  • Research Site
    Clearwater, Florida 33765, United States
  • Research Site
    Doral, Florida 33166, United States
  • Research Site
    Hialeah, Florida 33012, United States
  • Research Site
    Hollywood, Florida 33024, United States
  • Research Site
    Lake Worth, Florida 33467, United States
  • Research Site
    Miami, Florida 33165, United States
  • Research Site
    Miami, Florida 33173, United States
  • Research Site
    Pembroke Pines, Florida 33027, United States
  • Research Site
    Winter Haven, Florida 33880, United States
  • Research Site
    Addison, Illinois 60101, United States
  • Research Site
    Chicago, Illinois 60607, United States
  • Research Site
    Morton, Illinois 61550, United States
  • Research Site
    Brownsburg, Indiana 46112, United States
  • Research Site
    New Orleans, Louisiana 70124, United States
  • Research Site
    Troy, Michigan 48085, United States
  • Research Site
    Olive Branch, Mississippi 38654, United States
  • Research Site
    Brooklyn, New York 11235, United States
  • Research Site
    Columbus, Ohio 43213, United States
  • Research Site
    Edmond, Oklahoma 73013, United States
  • Research Site
    Austin, Texas 78705, United States
  • Research Site
    Carrollton, Texas 75006, United States
  • Research Site
    Dallas, Texas 75234, United States
  • Research Site
    Georgetown, Texas 78628, United States
  • Research Site
    Houston, Texas 77040, United States
  • Research Site
    Lampasas, Texas 76550, United States
  • Research Site
    San Antonio, Texas 78209, United States
  • Research Site
    West Valley City, Utah 84120, United States
  • Research Site
    Manassas, Virginia 20110, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Nov 2023, 19 months.

Results were first posted in Dec 2024, 1 year 1 month after primary completion.

Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 19 months is above that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2022
First posted
Jul 15, 2022
StartActual
Apr 6, 2022
Primary completionActual
Nov 7, 2023
CompletionActual
Nov 7, 2023
Results first posted
Dec 16, 2024
Last update
Dec 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05459688
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 15, 2022
Start date
Apr 6, 2022
Primary completion
Nov 7, 2023
Completion
Nov 7, 2023
Results posted
Dec 16, 2024
Last update
Dec 16, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baxdrostat

Start the discussion